| The somatic genomic landscape of chromophobe renal cell carcinoma CF Davis, CJ Ricketts, M Wang, L Yang, AD Cherniack, H Shen, C Buhay, ... Cancer cell 26 (3), 319-330, 2014 | 804 | 2014 |
| Dual chromatin and cytoskeletal remodeling by SETD2 IY Park, RT Powell, DN Tripathi, R Dere, TH Ho, TL Blasius, YC Chiang, ... Cell 166 (4), 950-962, 2016 | 227 | 2016 |
| Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects JM Simon, KE Hacker, D Singh, AR Brannon, JS Parker, M Weiser, TH Ho, ... Genome research 24 (2), 241-250, 2014 | 205 | 2014 |
| Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology AR Brannon, SM Haake, KE Hacker, RS Pruthi, EM Wallen, ME Nielsen, ... European urology 61 (2), 258-268, 2012 | 115 | 2012 |
| Structure/function analysis of recurrent mutations in SETD2 protein reveals a critical and conserved role for a SET domain residue in maintaining protein stability and histone … KE Hacker, CC Fahey, SA Shinsky, YCJ Chiang, JV DiFiore, DK Jha, ... Journal of Biological Chemistry 291 (40), 21283-21295, 2016 | 71 | 2016 |
| VHL type 2B mutations retain VBC complex form and function KE Hacker, CM Lee, WK Rathmell PloS one 3 (11), e3801, 2008 | 40 | 2008 |
| Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer NR Rasmussen, TM Wright, SA Brooks, KE Hacker, Z Debebe, AB Sendor, ... Journal of Biological Chemistry 288 (36), 26301-26310, 2013 | 34 | 2013 |
| Cancer Genome Atlas Research N CF Davis, CJ Ricketts, M Wang, L Yang, AD Cherniack, H Shen, C Buhay, ... Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske …, 2014 | 26 | 2014 |
| Detection of upper tract urothelial malignancies by computed tomography urography in patients referred for hematuria at a large tertiary referral center CW Commander, DC Johnson, MC Raynor, LM Burke, KE Hacker, ... Urology 102, 31-37, 2017 | 24 | 2017 |
| Tumor suppressive activity of prolyl isomerase Pin1 in renal cell carcinoma BL Teng, KE Hacker, S Chen, AR Means, WK Rathmell Molecular oncology 5 (5), 465-474, 2011 | 20 | 2011 |
| SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition EA Terzo, AR Lim, A Chytil, YC Chiang, L Farmer, KH Gessner, CL Walker, ... Oncotarget 10 (6), 647, 2019 | 12 | 2019 |
| Engaging stakeholders and patient partners KE Hacker, AB Smith Surgical Oncology Clinics 27 (4), 665-673, 2018 | 9 | 2018 |
| Emerging molecular classification in renal cell carcinoma: implications for drug development KE Hacker, WK Rathmell Targeted oncology 5, 75-84, 2010 | 9 | 2010 |
| Implementation of postoperative standard opioid prescribing schedules reduces opioid prescriptions without change in patient-reported pain outcomes KH Gessner, J Jung, HE Cook, JL Graves, P McNaull, B Chidgey, J Mann, ... Urology 148, 126-133, 2021 | 7 | 2021 |
| Von Hippel-Lindau status influences phenotype of liver cancers arising from PTEN loss AB Sendor, KE Hacker, S Chen, AL Corona, O Sen, DY Chiang, ... Gastrointestinal cancer: targets and therapy, 61-71, 2015 | 6 | 2015 |
| Postoperative opioid prescribing in urology: Are we contributing to the national crisis? KE Hacker, J Jung, JL Graves, HE Cook, P McNaull, BA Chidgey, J Mann, ... Journal of the American College of Surgeons 227 (4), e166, 2018 | 3 | 2018 |
| MP80-11 post-operative opioid prescribing in urology: are we contributing to the national crisis? K Hacker, J Jung, JL Graves, H Cook, P McNaull, B Chidgey, J Mann, ... The Journal of Urology 199 (4S), e1093-e1093, 2018 | 2 | 2018 |
| Investigating the role of SETD2 mutations and H3K36me3 loss in clear cell Renal Cell Carcinoma KE Hacker The University of North Carolina at Chapel Hill, 2014 | 1 | 2014 |
| National Variation in Opioid Prescription Fills and Long-Term Use in Opioid Naive Patients after Urological Surgery EDITORIAL COMMENT KH Gessner, ME Nielsen JOURNAL OF UROLOGY 202 (5), 1044-1045, 2019 | | 2019 |
| Correction: SETD2 loss sensitizes cells to PI3Kβ and AKT inhibition EA Terzo, AR Lim, A Chytil, YC Chiang, L Farmer, KH Gessner, CL Walker, ... Oncotarget 10 (59), 6391, 2019 | | 2019 |
